Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (871-880 of 1,060) with videos related to

Pageof 106
Sort By:
European Journal of Heart Failure|February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysisLuis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal|February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HFMichael Böhm, Robin Young, Pardeep S Jhund, et al.
European Journal of Heart Failure|May 27, 2015
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapyMichael R Zile, William T Abraham, Fred A Weaver, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
Frontiers in Neuroscience|December 13, 2023
Predictors of futile recanalization after endovascular treatment in acute ischemic stroke: a multi-center studyYu Sun, Eric Jou, Thanh N Nguyen, et al.
Circulation. Heart Failure|May 28, 2026
Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HFAkshay S Desai, Michael R Zile, Anique Ducharme, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Journal of the American College of Cardiology|May 27, 2026
Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF TrialJaved Butler, Rami Kahwash, Muhammad Shahzeb Khan, et al.
JACC. Basic to Translational Science|January 8, 2020
Seipin Knockout Mice Develop Heart Failure With Preserved Ejection FractionBo Bai, Wulin Yang, Yanyun Fu, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Pageof 106

Showing results (871-880 of 1,060) with videos related to

Sort By:
Pageof 106
European Journal of Heart Failure|February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysisLuis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal|February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HFMichael Böhm, Robin Young, Pardeep S Jhund, et al.
European Journal of Heart Failure|May 27, 2015
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapyMichael R Zile, William T Abraham, Fred A Weaver, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
Frontiers in Neuroscience|December 13, 2023
Predictors of futile recanalization after endovascular treatment in acute ischemic stroke: a multi-center studyYu Sun, Eric Jou, Thanh N Nguyen, et al.
Circulation. Heart Failure|May 28, 2026
Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HFAkshay S Desai, Michael R Zile, Anique Ducharme, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Journal of the American College of Cardiology|May 27, 2026
Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF TrialJaved Butler, Rami Kahwash, Muhammad Shahzeb Khan, et al.
JACC. Basic to Translational Science|January 8, 2020
Seipin Knockout Mice Develop Heart Failure With Preserved Ejection FractionBo Bai, Wulin Yang, Yanyun Fu, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Pageof 106